QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View

Title:QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View

Volume: 11 Issue: 3

Author(s): Francesca Aroldi, Tiziana Prochilo, Elena Bonini and Alberto Zaniboni

Affiliation:

Keywords: Adverse cardiac events, cancer, QT prolongation, through QT study, torsade de point.

Abstract: Currently, many novel therapies are available for physicians treating cancer; some of them are associated with adverse cardiac events. One of the most worrisome cardiac event is QT prolongation, which is a risk factor for developing the potentially fatal torsade de pointe. Many classes of drugs, both anticancer and concomitant agents, are involved in this issue. We report a review of old and new commonly used agents with torsadogenic potential.

Cite this article as:

Aroldi Francesca, Prochilo Tiziana, Bonini Elena and Zaniboni Alberto, QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View, Reviews on Recent Clinical Trials 2016; 11 (3) . https://dx.doi.org/10.2174/1574887111666160226150650